S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NYSE:PRGO

Perrigo - PRGO Stock Forecast, Price & News

$33.98
-0.59 (-1.71%)
(As of 03/22/2023 05:24 PM ET)
Add
Compare
Today's Range
$33.97
▼
$34.63
50-Day Range
$34.57
▼
$38.75
52-Week Range
$30.78
▼
$43.90
Volume
1.39 million shs
Average Volume
1.12 million shs
Market Capitalization
$4.58 billion
P/E Ratio
N/A
Dividend Yield
3.21%
Price Target
$48.00

Perrigo MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
41.3% Upside
$48.00 Price Target
Short Interest
Bearish
4.18% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.93
Upright™ Environmental Score
News Sentiment
0.32mentions of Perrigo in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$619,867 Sold Last Quarter
Proj. Earnings Growth
17.83%
From $2.58 to $3.04 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.06 out of 5 stars

Medical Sector

26th out of 983 stocks

Pharmaceutical Preparations Industry

6th out of 478 stocks

See Top Rated MarketRank™ Stocks Here

PRGO stock logo

About Perrigo (NYSE:PRGO) Stock

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Stock News Headlines

March 21, 2023 | finance.yahoo.com
More Baby-Formula Issues: This Big Brand Is Being Recalled Now
March 20, 2023 | finance.yahoo.com
Some Gerber Baby Formula Recalled Due to Possible Contamination
March 22, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 17, 2023 | americanbankingnews.com
Insider Selling: Perrigo Company plc (NYSE:PRGO) EVP Sells $321,300.00 in Stock
March 17, 2023 | americanbankingnews.com
Zacks Research Brokers Decrease Earnings Estimates for Perrigo Company plc (NYSE:PRGO)
March 17, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Perrigo Company plc Reduced by Zacks Research (NYSE:PRGO)
March 16, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Perrigo (NYSE:PRGO)
March 15, 2023 | americanbankingnews.com
Perrigo Company plc (NYSE:PRGO) EVP Sells $132,427.11 in Stock
March 22, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 12, 2023 | americanbankingnews.com
Perrigo Company plc (NYSE:PRGO) EVP Ronald Craig Janish Sells 4,500 Shares
March 10, 2023 | benzinga.com
Insiders Selling Perrigo And 3 Other Stocks
March 7, 2023 | seekingalpha.com
Perrigo a new buy at Canaccord Genuity with focus on self-care products, cost savings
March 6, 2023 | markets.businessinsider.com
Raymond James Reaffirms Their Buy Rating on Perrigo Company (PRGO)
March 2, 2023 | finance.yahoo.com
Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference
March 1, 2023 | finance.yahoo.com
Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets
February 28, 2023 | finance.yahoo.com
Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day
February 28, 2023 | finance.yahoo.com
Perrigo (PRGO) Tops Q4 Earnings Estimates
February 27, 2023 | finance.yahoo.com
Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations
February 21, 2023 | finance.yahoo.com
Perrigo Increases its Quarterly Dividend
February 21, 2023 | finance.yahoo.com
Perrigo raises quarterly dividend by 5% to 27.30 cents a share
February 20, 2023 | finance.yahoo.com
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
February 14, 2023 | finance.yahoo.com
Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023
December 26, 2022 | thestreet.com
Perrigo (PRGO) Stock Plunging on Failed Mylan Deal
December 19, 2022 | finance.yahoo.com
Perrigo to Host Virtual Investor Day on February 28, 2023
December 16, 2022 | finance.yahoo.com
SWEDEN’S SKINCARE SENSATION ACO EXTENDS PRESENCE INTO US TIMED TO THE HOLIDAY SEASON
December 16, 2022 | investing.com
Perrigo Co. PT Lowered to $45 at JPMorgan
December 1, 2022 | finance.yahoo.com
Reckitt Benckiser expects baby formula shortage to continue into spring 2023
See More Headlines
Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Company Calendar

Last Earnings
2/27/2023
Ex-Dividend for 3/28 Dividend
3/09/2023
Today
3/22/2023
Dividend Payable
3/28/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:PRGO
CUSIP
71429010
CIK
1585364
Web
www.perrigo.com
Phone
(531) 709-4000
Fax
269-673-9128
Employees
8,900
Year Founded
1887

Price Target and Rating

Average Stock Price Forecast
$48.00
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+38.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
13.40
P/E Growth
N/A
Net Income
$-140,600,000.00
Net Margins
-2.91%
Pretax Margin
-3.12%
Return on Equity
5.79%
Return on Assets
2.61%

Debt

Debt-to-Equity Ratio
0.84
Current Ratio
2.44
Quick Ratio
1.41

Sales & Book Value

Annual Sales
$4.45 billion
Price / Sales
1.05
Cash Flow
$4.57 per share
Price / Cash Flow
7.57
Book Value
$35.96 per share
Price / Book
0.96

Miscellaneous

Outstanding Shares
134,650,000
Free Float
133,571,000
Market Cap
$4.65 billion
Optionable
Optionable
Beta
0.79

Social Links


Key Executives

  • Murray S. Kessler
    President, Chief Executive Officer & Director
  • Ronald C. JanishRonald C. Janish
    Executive VP-Global Operations and Supply Chain
  • Eduardo Guarita Bezerra
    Chief Financial Officer & Executive Vice President
  • Thomas M. FarringtonThomas M. Farrington
    Chief Information Officer & Executive VP
  • Grainne Quinn
    Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRGO Stock - Frequently Asked Questions

Should I buy or sell Perrigo stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRGO shares.
View PRGO analyst ratings or view top-rated stocks.

What is Perrigo's stock price forecast for 2023?

4 equities research analysts have issued 12-month price objectives for Perrigo's shares. Their PRGO share price forecasts range from $43.00 to $54.00. On average, they anticipate the company's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price.
View analysts price targets for PRGO or view top-rated stocks among Wall Street analysts.

How have PRGO shares performed in 2023?

Perrigo's stock was trading at $34.09 at the beginning of 2023. Since then, PRGO stock has increased by 1.4% and is now trading at $34.57.
View the best growth stocks for 2023 here.

When is Perrigo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our PRGO earnings forecast.

How were Perrigo's earnings last quarter?

Perrigo Company plc (NYSE:PRGO) released its earnings results on Monday, February, 27th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.70 by $0.05. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.20 billion. Perrigo had a negative net margin of 2.91% and a positive trailing twelve-month return on equity of 5.79%. The business's revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.60 earnings per share.

How often does Perrigo pay dividends? What is the dividend yield for Perrigo?

Perrigo declared a quarterly dividend on Tuesday, February 21st. Investors of record on Friday, March 10th will be paid a dividend of $0.273 per share on Tuesday, March 28th. This represents a $1.09 annualized dividend and a yield of 3.16%. The ex-dividend date is Thursday, March 9th. This is a positive change from the stock's previous quarterly dividend of $0.26.
Read our dividend analysis for PRGO.

What ETFs hold Perrigo's stock?

ETFs with the largest weight of Perrigo (NYSE:PRGO) stock in their portfolio include Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Dynamic Pharmaceuticals ETF (PJP), AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF (SMIG), iShares U.S. Pharmaceuticals ETF (IHE), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL), Cultivar ETF (CVAR) and VanEck Pharmaceutical ETF (PPH).

Is Perrigo a good dividend stock?

Perrigo (NYSE:PRGO) pays an annual dividend of $1.09 per share and currently has a dividend yield of 3.14%.
Read our dividend analysis for PRGO.

What guidance has Perrigo issued on next quarter's earnings?

Perrigo issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of $2.50-$2.70 for the period, compared to the consensus earnings per share estimate of $2.78. The company issued revenue guidance of $4.76 billion-$4.94 billion, compared to the consensus revenue estimate of $4.80 billion.

What is Murray S. Kessler's approval rating as Perrigo's CEO?

38 employees have rated Perrigo Chief Executive Officer Murray S. Kessler on Glassdoor.com. Murray S. Kessler has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Perrigo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), AbbVie (ABBV), Allergan (AGN), Intel (INTC), Johnson & Johnson (JNJ), Netflix (NFLX), QUALCOMM (QCOM) and Amgen (AMGN).

What is Perrigo's stock symbol?

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Who are Perrigo's major shareholders?

Perrigo's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Barrow Hanley Mewhinney & Strauss LLC (7.30%), Dimensional Fund Advisors LP (4.77%), Cooke & Bieler LP (2.91%), Coho Partners Ltd. (2.67%), DAVENPORT & Co LLC (2.23%) and Thompson Siegel & Walmsley LLC (2.14%). Insiders that own company stock include Bradley A Alford, Geoffrey M Parker, Grainne Quinn, James E Dillard III, Raymond Silcock, Richard S Sorota, Rolf A Classon, Ronald Craig Janish, Svend Andersen, Theodore R Samuels II, Thomas Farrington and Todd W Kingma.
View institutional ownership trends.

How do I buy shares of Perrigo?

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Perrigo's stock price today?

One share of PRGO stock can currently be purchased for approximately $34.57.

How much money does Perrigo make?

Perrigo (NYSE:PRGO) has a market capitalization of $4.65 billion and generates $4.45 billion in revenue each year. The company earns $-140,600,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

How many employees does Perrigo have?

The company employs 8,900 workers across the globe.

Does Perrigo have any subsidiaries?
The following companies are subsidiares of Perrigo: 010414 UK Limited, 251211 UK Limited, Abtei Omega Pharma GmbH, Aco Hud Nordic AB, Adriatic BST Trgovina in Storitve D.o.o., Adriatic Distribution doo Beograd, Agis Industries, Algorithmics Risk Management Limited, Arginet Investments and Property (2003) Ltd., Athena Neurosciences LLC, Aurora Pharmaceuticals Pty Ltd, Biover NV, Blue Wolf Global Limited, Bluewolf International Limited, Brunel Healthcare Manufacturing Limited, CP Kayak Holdings Inc., CanNegev Ltd, Chefaro Ireland Designated Activity Company, Cinetic Laboratories Argentina SA, Cleversafe UK Limited, Cosmediet - Biotechnie SAS, Despharma Kft., Elan Corporation, Elan Europa Finance S.á r.l., Elan International Services Limited, Elan Pharmaceuticals LLC, Fera Pharmaceuticals, Galpharm Healthcare Limited, Galpharm International, Galpharm International Limited, Geiss Destin & Dunn, Gelcaps Exportadora de Mexico S.A. de C.V., Gr8ness LLC, HRA Pharma, Habsont Unlimited Company, Heartbeat Experts Limited, IBM GF international Treasury Company, IBM International Treasury Services Unlimited Company, IBM Netherlands Treasury B.V., Interdelta S.A., International Business Machines Limited, Irish Biosciences Venture Capital Fund, JB Laboratories, JLR Pharma S.A., Jaico R.D.P. NV, Jewel Consumer Care Pvt. Ltd., Kazmira LLC, Kenexa Global Recruitment Services Limited, Kenexa Quorum Holdings Limited, Kenexa Technology LLC, Kiteacre Limited, L. Perrigo Company, Laboratoire de la Mer SAS, Laboratoires Omega Pharma France SAS, Laboratorios DIBA S.A., Laboratorios Diba, Luxembourg Investment Company 289 Sàrl, MH (UK) Limited, Medgenix Benelux NV, Monksland Holdings B.V., Naturwohl Pharma GmbH, ORION Laboratories, Oce Bio BV, Oce-Bio Nederland B.V., Omega Alpharm Cyprus Ltd., Omega Pharma, Omega Pharma AS, Omega Pharma Australia Pty Ltd, Omega Pharma Austria Healthcare GmbH, Omega Pharma Baltics SIA, Omega Pharma Belgium NV, Omega Pharma Capital NV, Omega Pharma Deutschland GmbH, Omega Pharma GmbH, Omega Pharma Hellas SA Health and Beauty Products, Omega Pharma Hungary Kft., Omega Pharma Innovation & Development NV, Omega Pharma International NV, Omega Pharma Limited, Omega Pharma Luxembourg SarL, Omega Pharma Manufacturing GmbH & Co. KG, Omega Pharma Manufacturing Verwaltungs GmbH, Omega Pharma Nederland B.V., Omega Pharma Trading NV, Omega Pharma s.r.o., Omega Teknika Designated Activity Company, OmegaLabs (Pty) Ltd, Oniqua Europe Limited, Optevia Limited, Orion Laboratories (NZ) Ltd., Orion Laboratories PTY Limited, P-Direct NL B.V., P2C Inc., PBM Canada Holdings LLC, PBM China Holdings LLC, PBM Foods LLC, PBM Holdings LLC, PBM International Holdings LLC, PBM Mexico Holdings LLC, PBM Nutritionals LLC, PBM Products, PBM Products LLC, PBM Products Mexico S de R.L. de C.V., PMI Branded Pharmaceuticals Inc., Paddock Laboratories, Paracelsia Pharma GmbH, Perrigo Asia Holding Company Ltd., Perrigo Australian Holding Company II PTY Limited, Perrigo Bulgaria OOD, Perrigo China Business Trust, Perrigo China Business Trustee LLC, Perrigo Company, Perrigo Company Charitable Foundation, Perrigo Company of Tennessee, Perrigo Company plc, Perrigo Corporation Designated Activity Company, Perrigo Danmark A/S, Perrigo Diabetes Care LLC, Perrigo Direct Inc., Perrigo España SA, Perrigo Europe Invest NV, Perrigo Finance (US) LLC, Perrigo Finance Unlimited Company, Perrigo Florida Inc., Perrigo France SAS, Perrigo Global Holdings Inc., Perrigo Holding NV, Perrigo Holdings Unlimited Company, Perrigo International Finance Designated Activity Company, Perrigo International Holdings II Inc., Perrigo International Holdings LLC, Perrigo International Inc., Perrigo International Insurance Limited, Perrigo Ireland 1 Designated Activity Company, Perrigo Ireland 10 Unlimited Company, Perrigo Ireland 11 DAC, Perrigo Ireland 12 Designated Activity Company, Perrigo Ireland 13 Designated Activity Company, Perrigo Ireland 2 Designated Activity Company, Perrigo Ireland 3 Designated Activity Company, Perrigo Ireland 4 Unlimited Company, Perrigo Ireland 5 Unlimited Company, Perrigo Ireland 6 Unlimited Company, Perrigo Ireland 7 Designated Activity Company, Perrigo Ireland 8 Designated Activity Company, Perrigo Ireland 9 Unlimited Company, Perrigo Ireland Holding Company B.V., Perrigo Ireland Management Designated Activity Company, Perrigo Israel Enterprises & Investments Ltd., Perrigo Israel Holdings II B.V., Perrigo Israel Opportunities II Ltd., Perrigo Israel Trading Limited Partnership, Perrigo Italia S.r.l, Perrigo Kişisel Bakım Ürünleri Sanayi ve Ticaret Limited Şirketi, Perrigo LLC, Perrigo Laboratories India Private Limited, Perrigo Management Company, Perrigo Mexico Holding S.A. de C.V., Perrigo Mexico Investment Holdings LLC, Perrigo Netherlands B.V., Perrigo Netherlands Finco 1 Coöperatief U.A., Perrigo Netherlands Finco 2 B.V., Perrigo Netherlands International Partnership C.V., Perrigo New York Inc., Perrigo Norge AS, Perrigo Oral Health Care Holdings Inc., Perrigo Pharma Holding Nederland BV, Perrigo Pharma International Designated Activity Company, Perrigo Pharma Limited, Perrigo Poland Sp.z.o.o, Perrigo Portugal LDA, Perrigo Research & Development Company, Perrigo România S.R.L., Perrigo Sales Corporation, Perrigo Science Eight Unlimited Company, Perrigo Science One Designated Activity Company, Perrigo Suomi Oy, Perrigo Sverige AB, Perrigo Trading (Shanghai) Co. Ltd., Perrigo UK Acquisition Limited, Perrigo UK Finco Limited Partnership, Perrigo Ukraine LLC, Perrigo Ventures Limited Partnership, Perrigo de Mexico S.A. de C.V., Perrigo do Brasil Farmaceutica Ltda., Pharma Clal (1983) Ltd., Promontory Financial Group (UK) Limited, Quimica y Farmacia S.A. de C.V., Ranir, Ranir (Holdings) Limited, Ranir Changshu Oral Care CO. Ltd., Ranir Global Holdings LLC, Ranir LLC, Ranir Limited, Resilient Systems Europe Limited, Richard Bittner AG, Rosemont Pharmaceuticals, Rubicon Healthcare Holdings Pty Ltd, SPSS Limited, Samenwerkende Apothekers Nederland B.V., ScarAway, Silverpop Systems Limited, Simpler Consulting Limited, Solent Dental Company Limited, Solent Oral Care Limited, Sterling Commerce (UK) Limited, The Analytic Sciences Corporation Limited, The Learning Pharmacy Limited, The Weather Channel Global Media Limited, Totalcare International Corp, Transitive Corporation Limited, Transitive Limited, Truven Health Analytics UK Limited, Velcera, Weather Services International Limited, Wrafton Laboratories, Wrafton Laboratories Limited, Zibo Xinhua - Perrigo Pharmaceutical Company Ltd., i2 Holdings Limited, i2 Intermediate Holdings Limited, and i2 Limited.
Read More
How can I contact Perrigo?

Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The official website for the company is www.perrigo.com. The company can be reached via phone at (531) 709-4000, via email at bradley.joseph@perrigo.com, or via fax at 269-673-9128.

This page (NYSE:PRGO) was last updated on 3/22/2023 by MarketBeat.com Staff